MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

MDT

83.38

+1.89%↑

VEEV

215.75

+2.79%↑

A

102.85

+2.55%↑

WBA

10.98

+1.1%↑

CHE

579.48

+2.88%↑

Search

Incyte Corp

Fermé

SecteurSoins de santé

57.37 1

Résumé

Variation du prix de l'action

24h

Actuel

Min

56.72

Max

57.59

Chiffres clés

By Trading Economics

Revenu

95M

201M

Ventes

39M

1.2B

P/E

Moyenne du Secteur

378.667

57.333

BPA

1.43

Marge bénéficiaire

17.071

Employés

2,617

EBITDA

145M

337M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+30.05% upside

Dividendes

By Dow Jones

Prochains Résultats

29 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-5.4B

11B

Ouverture précédente

56.37

Clôture précédente

57.37

Sentiment de l'Actualité

By Acuity

52%

48%

322 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 avr. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Union Says Nippon Steel Can't Be Trusted With Buying U.S. Steel

22 avr. 2025, 20:55 UTC

Résultats

Intuitive Surgical Reports Higher 1Q Profit, Warns of Tariff Hit to Margins

22 avr. 2025, 23:49 UTC

Market Talk

Nikkei May Rise After Wall Street Rally -- Market Talk

22 avr. 2025, 23:49 UTC

Market Talk

Gold Falls on Signs of Easing U.S.-China Tensions, Possible Profit-Taking -- Market Talk

22 avr. 2025, 23:47 UTC

Actualités

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 4th Update

22 avr. 2025, 23:08 UTC

Acquisitions, Fusions, Rachats

Woodside: No Change to Annual Guidance

22 avr. 2025, 23:07 UTC

Acquisitions, Fusions, Rachats

Woodside: Assessing Impacts of Recent Tariff Announcements on Louisiana LNG

22 avr. 2025, 23:07 UTC

Acquisitions, Fusions, Rachats

Woodside: Advancing Talks Targeting Further Equity Selldown in Louisiana LNG

22 avr. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

Woodside: Trion Project 26% Complete, on Track for First Oil in 2028

22 avr. 2025, 23:05 UTC

Acquisitions, Fusions, Rachats

Woodside: Scarborough Energy Project on Track for First LNG Cargo in 2H 2026

22 avr. 2025, 23:05 UTC

Acquisitions, Fusions, Rachats

Woodside Energy: Scarborough Energy Project 82% Complete

22 avr. 2025, 23:05 UTC

Acquisitions, Fusions, Rachats

Woodside Energy: Beaumont New Ammonia Project on Track to Start in 2H

22 avr. 2025, 23:05 UTC

Acquisitions, Fusions, Rachats

Woodside Energy: Beaumont New Ammonia Project 90% Complete

22 avr. 2025, 23:04 UTC

Acquisitions, Fusions, Rachats

Woodside Energy: Share of Sangomar Production Maintained at 78 Million Bbl/Day in 1Q

22 avr. 2025, 23:04 UTC

Market Talk
Acquisitions, Fusions, Rachats

Macquarie Set for A$500 Million Gain on Sale From Nomura Deal -- Market Talk

22 avr. 2025, 23:04 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Sold 25.4% of Produced LNG at Prices Linked to Gas Hub Indices in 1Q

22 avr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Woodside Energy Cites Lower Output, Reduced Oil-Linked Prices for Revenue Fall

22 avr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Woodside Energy 1Q Revenue Down 5% on Prior Quarter

22 avr. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Woodside Energy 1Q Revenue US$3.315 Billion

22 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Woodside Cites Weather Impacts at North West Shelf, Pluto Unplanned Outages in 1Q

22 avr. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Woodside Energy 1Q Oil, Natural Gas Output Down 4% on Prior Quarter

22 avr. 2025, 23:01 UTC

Acquisitions, Fusions, Rachats

Woodside Energy 1Q Oil, Natural Gas Output 49.1 Million BOE

22 avr. 2025, 22:31 UTC

Résultats

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- Update

22 avr. 2025, 22:26 UTC

Actualités

Trump Is Laying the Groundwork to Blame Powell for Any Downturn -- Update

22 avr. 2025, 22:16 UTC

Actualités

Trump Says He Has 'No Intention' of Firing Fed Chair Powell -- 3rd Update

22 avr. 2025, 22:16 UTC

Market Talk

Turkey Remains on Course for Steadily Lower Inflation, Finance Minister Says -- Market Talk

22 avr. 2025, 22:04 UTC

Actualités

China Tariffs 'Won't Be Anywhere Near' 145%: Trump -- Barrons.com

22 avr. 2025, 21:42 UTC

Résultats

Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role -- WSJ

22 avr. 2025, 21:21 UTC

Actualités
Résultats

Tesla Profit Sinks, Hurt by Political Backlash -- 3rd Update

22 avr. 2025, 21:19 UTC

Actualités

Investors Hope for No Surprises as Boeing Reports Earnings -- Barrons.com

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

30.05% hausse

Prévisions sur 12 Mois

Moyen 73.87 USD  30.05%

Haut 92 USD

Bas 52 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

6

Achat

11

Maintien

1

Vente

Score Technique

By Trading Central

55.17 / 56.97Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

322 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation